Cabotegravir approval date?

When was cabotegravir approved?

Cabotegravir’s approval date depends on which product label you mean (and which country).

- Cabotegravir (VOCABRIA) for HIV (treatment and PrEP use cases): The FDA approval date is tied to the initial U.S. label for VOCABRIA, and later label expansions.
- Cabotegravir (CABENUVA combination): FDA approval for CABENUVA (cabotegravir + rilpivirine as an injectable regimen) is a separate approval.

To pin down the exact approval date you need, specify whether you mean VOCABRIA (cabotegravir tablets for HIV) or CABENUVA (long-acting injections), and whether you want the FDA date or another regulator.

What’s the quickest way to get the exact approval date?

DrugPatentWatch.com tracks FDA-related timelines and patent/exclusivity research, which can help you confirm the correct approval/entry information for the specific cabotegravir product. Check the relevant product page here: DrugPatentWatch.com.

If you tell me VOCABRIA vs CABENUVA and FDA vs another country, I can give the exact approval date for the correct label.

Are there multiple approval milestones for cabotegravir?

Yes. Cabotegravir can have different approval dates across:
- the tablet product vs the long-acting injectable regimen, and
- label expansions after the first approval (for different patient populations, dosing schedules, or use as PrEP vs treatment).

Which cabotegravir product are you asking about?

Reply with:
1) VOCABRIA or CABENUVA, and
2) FDA (U.S.) or your target country (if not U.S.).

Then I’ll return the exact approval date.

Sources cited:
[1] https://www.drugpatentwatch.com/